The clinical value of "Hangzhou Criteria" in the selection of patients with hepatocellular carcinoma for liver transplantation: a report of 1163 cases on a multi-center basis
徐骁,杨家印,钟林,鲁迪,庄润周,屠振华,陈峻,王伟林,张珉
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2013.09.004
2013-01-01
Abstract:Objective To explore a valid candidate selecting criteria for liver transplantation (LT) in patients with primary hepatocellular carcinoma (HCC),and to investigate the clinical value of Hangzhou Criteria.Method This study retrospectively reviewed 1163 HCC patients undergoing LT,and the characteristics of recruited recipient population and the prognosis-predicting ability of different criteria were compared.Result In the 1163 recipients,the number of patients fulfilling Milan Criteria,Hangzhou Criteria,and UCSF Criteria was 424 (36.4％),645 (55.5％),and 484(41.6％),retrospectively.Compared to Milan Criteria,Hangzhou Criteria and UCSF Criteria provided an expansion of 52.1％ and 14.2％,respectively.For non-cirrhosis HCC patients,Hangzhou Criteria could provide the largest expansion to the candidate pool,which was 133.3％.For the recipients fulfilling different criteria,the prognosis was comparable.Hangzhou Criteria functioned well in predicting tumor-recurrence.The 1-,3-,and 5-years overall survival rate for patients fulfilling Hangzhou Criteria was significantly higher than that of patients exceeding Hangzhou Criteria (85.9％,73.6％,and 66.4％ versus 60.7％,26.2％,and 20.7％,respectively,P＜0.001).And the1,3,and 5-year tumor-free survival rate for patients fulfilling Hangzhou Criteria was also significantly higher than that of patients exceeding Hangzhou Criteria (78.8％,65.1％,and 60.8％ versus 37.2％,20.0％,and 18.8％,respectively,P＜0.001).Conclusion There is no dispute in the ethics Committee and all the donor's family members about the usage of ECMO.The ECMO support DBCD could well control the warm ischemia,and obtain satisfactory curative effect of transplantation.